Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11131MR)

This product GTTS-WQ11131MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Dermatomyositis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11131MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5340MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ1223MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ5381MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ14755MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ3019MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ11964MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ2429MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW